Comparative Pharmacology
Head-to-head clinical analysis: EMLA versus PARACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMLA versus PARACAINE.
EMLA vs PARACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.
None Documented
None Documented
Clinical Note
moderateProparacaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."
Clinical Note
moderateProparacaine + Clemastine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."
Clinical Note
moderateProparacaine + Venlafaxine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."
Clinical Note
moderateAfter topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
2.5 hours; prolonged to 8 hours in cirrhosis due to reduced hepatic metabolism
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Renal: 90% (70% unchanged, 20% as paracainol glucuronide); Biliary/Fecal: 10%
Category C
Category C
Local Anesthetic
Local Anesthetic
Proparacaine + Nefazodone
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone."